Related Experiment Video

Updated: Feb 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.2K

Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure

Tsuneo Takenaka1, Yoichi Ohno2, Hiromichi Suzuki3

  • 11 Department of Medicine, International University of Health and Welfare, Tokyo, Japan.

Diabetes & Vascular Disease Research
|November 24, 2017
PubMed
Abstract

Insights

Sodium-glucose co-transporter type 2 inhibitors effectively lower central blood pressure and improve kidney function in diabetic patients. These findings suggest a class effect for these medications in managing cardiovascular risk factors.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Central blood pressure is a key predictor of cardiovascular events.
  • Type 2 diabetes mellitus (T2DM) often coexists with hypertension and nephropathy, increasing cardiovascular risk.
  • Sodium-glucose co-transporter type 2 inhibitors (SGLT2i) are a class of antidiabetic drugs with known cardiovascular benefits.

Purpose of the Study:

  • To evaluate the impact of SGLT2 inhibitors on central blood pressure in patients with T2DM, hypertension, and nephropathy.
  • To determine if different SGLT2 inhibitors have comparable effects on cardiovascular and renal parameters.

Main Methods:

  • A 6-month prospective study involving 102 patients with T2DM, hypertension, and nephropathy.
  • Patients received either canagliflozin, empagliflozin, or luseogliflozin.
  • Central blood pressure was measured using radial tonometry; other clinical parameters were monitored.

Main Results:

  • All three SGLT2 inhibitors significantly reduced brachial and central blood pressures.
  • These agents also improved glycemic control (HbA1c, casual blood sugar) and estimated glomerular filtration rate (eGFR).
  • A significant reduction in albuminuria was observed, with central systolic blood pressure correlating with these decreases.

Conclusions:

  • The observed comparable effects of different SGLT2 inhibitors on central blood pressure and renal parameters suggest a class effect.
  • SGLT2 inhibitors demonstrate efficacy in reducing central blood pressure and albuminuria, contributing to cardiovascular risk reduction in T2DM patients.
Keywords:
Agediureticsmetforminrenin–angiotensin systemtubuloglomerular feedback

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.8K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
612